Plain-English translation of NCT06979336 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can help people with moderate to severe ulcerative colitis—especially those whose condition hasn't improved with other available treatments. The study will compare different doses of the medication against a placebo (a dummy pill) for the first 12 weeks, then all participants will receive the active medication for an additional 40 weeks. Researchers want to understand how well this treatment works, how safe it is, and how your body processes it.
Ulcerative colitis can be very difficult to treat, and some people don't respond well to the medications currently available. This trial exists to find out whether this new medication offers hope for people whose condition hasn't improved with conventional or other advanced therapies.
You likely qualify if…
You likely don't qualify if…
You would first go through a 5-week screening period to confirm you qualify. Then you would enter a 12-week phase where you'd receive either the study medication or a placebo, depending on which group you're randomly assigned to. After those 12 weeks, you would continue in the study for an additional 40 weeks, and everyone—including those who received the placebo initially—would receive the active medication. Throughout the trial, you would have regular visits to check on your health, discuss how you're feeling, and have blood work or other tests done. After your last dose, there would be a follow-up period to monitor your safety.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States